Clinical Trials
24 trialsOSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Dana-Farber Cancer Institute
A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN
University of Kentucky
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Barbara Ann Karmanos Cancer Institute
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Radiation Therapy Oncology Group
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Masonic Cancer Center, University of Minnesota
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Case Comprehensive Cancer Center
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
National Cancer Institute (NCI)
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
University of Michigan Rogel Cancer Center
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Dana-Farber Cancer Institute
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
Radiation Therapy Oncology Group
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Vanderbilt-Ingram Cancer Center